Axsome Therapeutics (NASDAQ:AXSM) reported a surge in full-year 2025 revenue on Monday, fueled by the rapid commercial scaling of its depression and sleep disorder treatments.
The New York-based biopharmaceutical firm delivered total net product revenue of $638.5 million for 2025, a 66% jump over the previous year, while narrowing its annual net loss to $183.2 million.
The growth was anchored by AUVELITY®, Axsome’s treatment for major depressive disorder, which generated $507.1 million in 2025 net sales, up 74% year-over-year.
The company’s narcolepsy and obstructive sleep apnea drug, SUNOSI®, contributed $124.8 million, while the newly launched migraine treatment SYMBRAVO® added $6.6 million following its commercial debut in June 2025.
Strategic momentum has shifted toward the company’s late-stage pipeline, specifically AXS-05 for the treatment of Alzheimer’s disease agitation.
The FDA has granted Priority Review for the supplemental New Drug Application (sNDA) for this indication, setting a high-stakes PDUFA action date of April 30, 2026.
If approved, AXS-05 would address a condition affecting up to 76% of Alzheimer's patients, a market currently hampered by a lack of approved pharmacological options.
Beyond regulatory milestones, Axsome recently expanded its neuroscience footprint through the acquisition of AXS-17 (formerly AZD7325), a Phase 2-ready GABA-A receptor modulator for epilepsy, from Avenue Therapeutics.
The deal, completed in late 2025, includes an upfront payment of $0.3 million with potential milestones exceeding $80 million.
With $322.9 million in cash and equivalents as of year-end, management reaffirmed that its current capital is sufficient to fund operations until the company achieves positive cash flow.